Drug Trial Radar · NCT04478513
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jul 21, 2020
Primary completion
Dec 23, 2020
Study completion Dec 23, 2020
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase I, open-label, non-randomized, 2-period, fixed-sequence study in healthy volunteers who are either smokers or non-smokers, performed at a single Clinical Unit.
Conditions
- Healthy Volunteer/DDI Study
Interventions
AZD4635Drug
During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
FluvoxamineDrug
Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve from time zero to infinity (AUC)Time frame: Days 1-6 and Days 11-16
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)Time frame: Days 1-6 and Days 11-16
- Maximum observed plasma concentration (Cmax)Time frame: Days 1-6 and Days 11-16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.